Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12099739 | 0.72 | EPHX2 (0.45) | FFAR1KCNH2FPR2PROKR1CNR1 | |
| SCHEMBL1811615 | 0.71 | CNR1 (0.47) | CNR1 | |
| SCHEMBL12100032 | 0.69 | EPHX2 (0.39) | FFAR1HRH3KCNH2FPR2PROKR1 | |
| SCHEMBL12099998 | 0.68 | HRH3 (0.43) | HRH3KCNH2 | |
| SCHEMBL12099792 | 0.68 | FPR2 (0.39) | SCDFFAR1HRH3KCNH2FPR2 | |
| SCHEMBL12099396 | 0.67 | SCN9A (0.38) | FPR2PROKR1ACACB | |
| SCHEMBL12100063 | 0.67 | FFAR1 (0.39) | FFAR1HRH3KCNH2FPR2PROKR1 | |
| SCHEMBL12099311 | 0.66 | FPR2 (0.57) | FFAR1FPR2PROKR1ACACBGPR6 | |
| SCHEMBL12099791 | 0.66 | HRH3 (0.41) | FFAR1HRH3KCNH2GPR6 | |
| SCHEMBL5543282 | 0.66 | AKR1C3 (0.46) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | SCD 2367/4885FFAR1 793/4885HRH3 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.